The USC Norris Comprehensive Cancer Center (NCCC) is requesting $450,000 per year in Developmental Funds to be used for new investigator support to recruit faculty level scientists in areas of strategic need and to fund innovative pilot projects. These funds will be crucial to our success as we continue to expand the number of investigators supported by the NCCC to fill the newly constructed research space in the Harlyne Norris Research Tower (HNRT). The HNRT is approximately 70% occupied and still has space for an additional 15 investigators. All recruitments are strategic to the NCCC's goals and have been discussed at our leadership retreats, approved by our Cancer Center Leadership Council and Cancer Center Executive Committee and evaluated by our External Advisory Committee. We will allocate our new investigator support annually at the recommendation of the Cancer Center Director and with the advice of our External Advisory Committee and the approval of the Executive Committee. Pilot project funds will be allocated after the review and recommendation for funding by the Leadership Council through the Whittier Initiative. Developmental Funds awarded during the past five years were allocated primarily to the recruitment of new investigators. The remaining portion was used to fund innovative pilot projects and to establish new shared resources.

Public Health Relevance

Developmental Funds allow the NCCC to fund innovative pilot projects and hire additional investigators to perform translational research for the development of more effective prevention, diagnosis, treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-39
Application #
8589338
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-12-01
Project End
2015-11-30
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$457,709
Indirect Cost
$166,553
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Zhao, Yi; Wu, Kaijin; Wu, Yongfeng et al. (2018) Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol 11:113-121
Kahn, Michael (2018) Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators. Prog Mol Biol Transl Sci 153:209-244

Showing the most recent 10 out of 842 publications